Companies: 10,795·Total market cap: $144.5T

Caribou Biosciences, Inc.

Caribou Biosciences, Inc.

CRBUNASDAQHealthcare● Active

$1.64

+$0.04(+2.51%)

Market Cap$162160240

P/E Ratio—

52W High$3.535

52W Low$1.04

Avg Volume1.5M

Open$1.61

Beta2.33

Net Income Financials Revenue

Caribou Biosciences, Inc. (CRBU) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

CRBU · net income · updated Jun 15, 2026

Core profitability metrics

CRBU · net income · margin · TTM · CAGR

Net income was −$148.1M for FY2025 (fiscal year ending 2025-12-31), up 0.7% year-over-year. Net profit margin was -1327.4%.

FY2025 Net Income−$148.1M▲ +0.7% YoY

Trailing 12M (TTM)−$133.2Mtrailing 4 quarters sum

Net Profit Margin< −999%−$148.1M ÷ $11.2M

YoY Change+0.7%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 15, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · CRBU net income history · CRBU profit margin

Annual net income data

CRBU · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$148.1M▲ +0.7%-1327.4%$11.2M

FY2024Loss−$149.1M▼ 46.1%-1492.0%$10.0M

FY2023Loss−$102.1M▼ 2.7%-296.1%$34.5M

FY2022Loss−$99.4M▼ 48.6%-717.8%$13.9M

FY2021Loss−$66.9M▼ 95.1%-697.3%$9.6M

Net income vs peers (Healthcare)

CRBU vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Caribou Biosciences, Inc.YOU

CRBU

−$148.1M+0.7%-1327.4%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Caribou Biosciences, Inc. (CRBU) reported net income of −$148.1M for FY2025 (fiscal year ending 2025-12-31), up 0.7% year-over-year. The net profit margin was -1327.4% — meaning the company kept $-13.27 of every dollar of revenue as profit.

Caribou Biosciences, Inc. has not yet achieved annual profitability based on available data (7 fiscal years). The company has reported net losses across all available periods.

Caribou Biosciences, Inc.'s net profit margin was -1327.4% for FY2025, based on the latest annual results.

Investors sometimes search for "Caribou Biosciences, Inc. net worth" — the company's market capitalization is a separate figure from CRBU net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

CRBU net income · 4 questions

Caribou Biosciences, Inc. is not currently profitable on an annual basis. The company reported a net loss of $148.1M for FY2025.

is CRBU profitabledoes CRBU make a profitCRBU profitabilityCRBU profitable company

▸ Source: FMP /income-statement · GAAP · Caribou Biosciences, Inc. · Caribou Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026